{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:15Z","timestamp":1753891935722,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.561341","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T06:55:01Z","timestamp":1603436101000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: A Chronological Combination Treatment of Icotinib, Osimertinib, and Crizotinib on Lung Adenocarcinoma Guided by Serial Genetic Tests of Circulating Tumor DNA and Sediment Cell Genomic DNA From Pleural Effusion"],"prefix":"10.3389","volume":"10","author":[{"given":"Zhihua","family":"Miao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianhao","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjie","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhizheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongcai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoming","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shifu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhua","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","article-title":"Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing","volume":"150","author":"Imielinski","year":"2012","journal-title":"Cell."},{"key":"B2","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1056\/NEJMra1703413","article-title":"Precision diagnosis and treatment for advanced non\u2013small-cell lung cancer","volume":"377","author":"Reck","year":"2017","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2174\/1389202915666150511205313","article-title":"Clinical next generation sequencing for precision medicine in cancer","volume":"16","author":"Dong","year":"2015","journal-title":"Curr Genomics."},{"key":"B4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","article-title":"Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy","volume":"6","author":"Alix-Panabi\u00e8res","year":"2016","journal-title":"Cancer Discov."},{"key":"B5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/j.1349-7006.2006.00216.x","article-title":"High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients","volume":"97","author":"Kimura","year":"2006","journal-title":"Cancer Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/sj.bjc.6603428","article-title":"EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib","volume":"95","author":"Kimura","year":"2006","journal-title":"Br J Cancer."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1002\/ijc.22190","article-title":"Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer","volume":"119","author":"Soh","year":"2006","journal-title":"Int J Cancer."},{"key":"B8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.lungcan.2007.10.011","article-title":"Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer","volume":"60","author":"Zhang","year":"2008","journal-title":"Lung Cancer."},{"key":"B9","doi-asserted-by":"publisher","first-page":"67810","DOI":"10.18632\/oncotarget.18866","article-title":"Evaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients: a cross-platform comparison study","volume":"8","author":"Gu","year":"2017","journal-title":"Oncotarget."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA."},{"key":"B11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.critrevonc.2018.11.008","article-title":"Complexity of genome sequencing and reporting: next generation sequencing (NGS) technologies and implementation of precision medicine in real life","volume":"133","author":"Morganti","year":"2019","journal-title":"Crit Rev Oncol Hematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/9511","article-title":"Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo","volume":"5","author":"Sethi","year":"1999","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.molonc.2014.12.003","article-title":"Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types","volume":"9","author":"Lebofsky","year":"2015","journal-title":"Mol Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.lungcan.2010.11.007","article-title":"Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors","volume":"73","author":"Zhao","year":"2011","journal-title":"Lung Cancer."},{"key":"B15","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/annonc\/mdx017","article-title":"Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA","volume":"28","author":"Remon","year":"2017","journal-title":"Ann Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.1200\/JCO.2011.35.4928","article-title":"MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib","volume":"29","author":"Lennerz","year":"2011","journal-title":"J Clin Oncol."},{"key":"B17","first-page":"1044","article-title":"Circulating tumor DNA in colorectal cancer: opportunities and challenges","volume":"12","author":"Bi","year":"2020","journal-title":"Am J Transl Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3389\/fgene.2019.01118","article-title":"The use of circulating tumor DNA to monitor and predict response to treatment in colorectal cancer","volume":"10","author":"Reece","year":"2019","journal-title":"Front Genet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.gpb.2016.12.004","article-title":"Circulating tumor DNA as biomarkers for cancer detection","volume":"15","author":"Han","year":"2017","journal-title":"Genomics Proteomics Bioinformatics."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.7150\/thno.34070","article-title":"Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer","volume":"9","author":"Tong","year":"2019","journal-title":"Theranostics."},{"key":"B22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12890-015-0025-z","article-title":"Important prognostic factors for survival in patients with malignant pleural effusion","volume":"15","author":"Zamboni","year":"2015","journal-title":"BMC Pulm Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/0002-9343(77)90154-1","article-title":"Carcinomatous involvement of the pleura: an analysis of 96 patients","volume":"63","author":"Chernow","year":"1977","journal-title":"Am J Med."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.561341\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T06:55:04Z","timestamp":1603436104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.561341\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":23,"alternative-id":["10.3389\/fonc.2020.561341"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.561341","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2020,10,23]]},"article-number":"561341"}}